Novo Nordisk, Eli Lilly and Boehringer Ingelheim back bill to bring obesity drug coverage to Medicare

Despite the widespread hype surrounding new and powerful obesity medicines, the drugs are still out of reach for many Americans who could benefit.

One reason is that under current laws, Medicare is barred from covering obesity drugs. But under legislation backed by Novo Nordisk, Eli Lilly, Boehringer Ingelheim and many other organizations, a group of lawmakers aims to change that.